Immune-Onc Therapeutics is a cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights into the tumor microenvironment and immune-suppressive pathways to develop first-in-class biotherapeutics. The team recently closed a $73 mm Series B1 and B2 financing round led by Oceanpine capital.